The Health-EU Portal started issuing last week a multilingual newsletter, which aims to better inform European citizens on what is going on in the field of health at European and international level.

Chronic myeloid leukaemia (CML) can be considered as a paradigm for neoplasias that evolve through a multi-step process. CML is also one of the best examples of a disease that can be targeted by molecular therapy; however, the success of new 'designer drugs' is largely restricted to the chronic phase of the disease. If not cured at this stage, CML invariably progresses and transforms into an acute-type leukaemia undergoing a 'blast crisis'. The causes of this transformation are still poorly understood. What mechanisms underlie this progression, and are they shared by other common cancers?

Dasatinib (Sprycel) is accepted for restricted use for the treatment of adults with chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesylate ...more

Interesting article on mechanisms of resistance Imatinib more....

The current recommended first line therapy for newly diagnosed patients with CML is IM. However, despite the impressive responses achieved in the majority of patients, problems remain more ...

Summary perspective of the 5th Annual CML Conference in Manchester on 6th/7th October

Firstly, it is worth note that having attended the last 3 of these conferences, we feel that there has been a continual improvement over that period of time. The improvement has been shown through the level of attendance, the relationship development between patients/carers and the medical professionals and the level of understanding shown by lay attendees.

Every EU citizen should fully understand the importance of this document because one in three of us will contract cancer over our lifetime and one in four of us will die from it. Cancer is a disease type that will affect every single family in Europe and as such deserves our attention and support<a href="?q=warsawdeclaration"> more...</a>

A race against time... Patients' clamour for Gleevec began in spring 1999, as soon as the results of the first tests on CML patients spread. Thanks to the Internet they were aware of the drug from its early stages.

<IMG class="topleft" src="http://www.cmlsupport.org.uk/gfx/llambook.jpg" alt="image of book"></IMG>A practical, easy-to-use guide to leukemias and lymphomas, Understanding Leukemia and Lymphoma is an invaluable text for everyone involved with these conditions, from specialists in training to interested patients. Using straightforward terminology. <a href="http://www.amazon.com/exec/obidos/tg/detail/-/1841844098?v=glance">more....

(CML) is a form of chronic leukemia characterized by increased production of myeloid cells in the bone marrow. It is a type of myeloproliferative disease more...